Shares of Israel-based Mediwound Ltd. (Nasdaq:MDWD) rose 11.6 percent to $4.89 Tuesday on news that Nexobrid, its EMA-approved enzyme for removing dead and damaged tissue, or eschar, in adults with thermal burns met the primary and secondary endpoints of a U.S.-based pivotal phase III trial. Jeremy Goverman, a Harvard Medical School professor and principal investigator for the study, said that, among other benefits, the product might help him and other doctors forgo use of the foot-long razor blade sometimes used to remove burnt skin layer by layer in surgical excision.